Alcidion Group Ltd (ASX:ALC) MD and CEO Kate Quirke talked with Proactive's Stephen Gunnion about how the company is making waves in healthcare innovation. Alcidion is leveraging its Miya Precision platform to address inefficiencies in healthcare delivery by improving patient outcomes and driving cost reductions.
Quirke revealed that Alcidion is already having a $1 billion positive impact on healthcare spending, highlighting the effectiveness of the platform's data consolidation and augmented intelligence capabilities. She explained, “We're really effectively taking the investments that have been made in the last ten years and now using that data to improve patient outcomes.”
The discussion also touched on the company's innovative business model centred around subscription revenue from long-term contracts. Alcidion’s expanding presence in territories like South Australia, the UK, and potentially Canada, underscores its strategic flexibility and modular technology that adapts to market demands.